Compare BMEA & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.